CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells

Journal of Immunology

Volumn 193, Issue 10, 2014, Pages 5327-5337

  Gil, Margaret ^a   Komorowski, Marcin P ^a   Seshadri, Mukund ^a   Rokita, Hanna ^b   McGray, A J Robert ^a   Opyrchal, Mateusz ^a   Odunsi, Kunle O ^a   Kozbor, Danuta ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 10; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; STEM CELL FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CANCER STEM CELL; CELL COUNT; CELL KILLING; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; ID8 T CELL LINE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTIC INFILTRATION; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPHEROID CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA IN SITU; CELL PROLIFERATION; DENDRITIC CELL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PERITONEAL NEOPLASMS; PROCEDURES; SCID MOUSE; SECONDARY; SIGNAL TRANSDUCTION; TUMOR VOLUME; VACCINIA VIRUS;

ANIMALS; CARCINOMA IN SITU; CELL PROLIFERATION; CHEMOKINE CXCL12; DENDRITIC CELLS; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED C57BL; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; VACCINIA VIRUS;

EID: 84910148214     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400201     Document Type: Article

References (75)

1. Jemal, A., R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57: 43-66
2. Kajiyama, H., K. Shibata, M. Terauchi, K. Ino, A. Nawa, and F. Kikkawa. 2008. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 122: 91-99
3. Sorensen, E. W., S. A. Gerber, A. L. Sedlacek, V. Y. Rybalko, W. M. Chan, and E. M. Lord. 2009. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol. Res. 45: 185-194
4. Armstrong, D. 2010. Update on treatment options for newly diagnosed ovarian cancer. Clin. Adv. Hematol. Oncol. 8: 675-678
5. Shah, M. M., and C. N. Landen. 2014. Ovarian cancer stem cells: Are they real and why are they important? Gynecol. Oncol. 132: 483-489
6. Foster, R., R. J. Buckanovich, and B. R. Rueda. 2013. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 338: 147-157
7. Bapat, S. A., A. M. Mali, C. B. Koppikar, and N. K. Kurrey. 2005. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65: 3025-3029
8. Kryczek, I., S. Liu, M. Roh, L. Vatan, W. Szeliga, S. Wei, M. Banerjee, Y. Mao, J. Kotarski, M. S. Wicha, et al. 2012. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int. J. Cancer 130: 29-39
9. Steffensen, K. D., A. B. Alvero, Y. Yang, M. Waldstrøm, P. Hui, J. C. Holmberg, D. A. Silasi, A. Jakobsen, T. Rutherford, and G. Mor. 2011. Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. J. Oncol. 2011: 620523
10. Zhan, Q., C. Wang, and S. Ngai. 2013. Ovarian cancer stem cells: A new target for cancer therapy. Biomed. Res. Int. 2013: 916819
11. Zhang, S., C. Balch, M. W. Chan, H. C. Lai, D. Matei, J. M. Schilder, P. S. Yan, T. H. Huang, and K. P. Nephew. 2008. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68: 4311-4320
12. Liao, J., F. Qian, N. Tchabo, P. Mhawech-Fauceglia, A. Beck, Z. Qian, X. Wang, W. J. Huss, S. B. Lele, C. D. Morrison, and K. Odunsi. 2014. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS ONE 9: e84941
13. Sato, E., S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumorinfiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538-18543
14. Odunsi, K., F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. 2007. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 104: 12837-12842
15. Hwang, W. T., S. F. Adams, E. Tahirovic, I. S. Hagemann, and G. Coukos. 2012. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A metaanalysis. Gynecol. Oncol. 124: 192-198
16. Cojoc, M., C. Peitzsch, F. Trautmann, L. Polishchuk, G. D. Telegeev, and A. Dubrovska. 2013. Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco. Targets Ther. 6: 1347-1361
17. Gelmini, S., M. Mangoni, M. Serio, P. Romagnani, and E. Lazzeri. 2008. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J. Endocrinol. Invest. 31: 809-819
18. Visvader, J. E., and G. J. Lindeman. 2008. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8: 755-768
19. Kucia, M., R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak. 2005. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23: 879-894
20. Scotton, C. J., J. L. Wilson, K. Scott, G. Stamp, G. D. Wilbanks, S. Fricker, G. Bridger, and F. R. Balkwill. 2002. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62: 5930-5938
21. Kryczek, I., A. Lange, P. Mottram, X. Alvarez, P. Cheng, M. Hogan, L. Moons, S. Wei, L. Zou, V. Machelon, et al. 2005. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res. 65: 465-472
22. Kryczek, I., S. Wei, E. Keller, R. Liu, and W. Zou. 2007. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am. J. Physiol. Cell Physiol. 292: C987-C995
23. Orimo, A., P. B. Gupta, D. C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V. J. Carey, A. L. Richardson, and R. A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348
24. Obermajer, N., R. Muthuswamy, K. Odunsi, R. P. Edwards, and P. Kalinski. 2011. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 71: 7463-7470
25. Zou, W., V. Machelon, A. Coulomb-L'Hermin, J. Borvak, F. Nome, T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, et al. 2001. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 7: 1339-1346
26. Righi, E., S. Kashiwagi, J. Yuan, M. Santosuosso, P. Leblanc, R. Ingraham, B. Forbes, B. Edelblute, B. Collette, D. Xing, et al. 2011. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 71: 5522-5534
27. Curiel, T. J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J. R. Conejo-Garcia, L. Zhang, M. Burow, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10: 942-949
28. Devine, S. M., N. Flomenberg, D. H. Vesole, J. Liesveld, D. Weisdorf, K. Badel, G. Calandra, and J. F. DiPersio. 2004. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22: 1095-1102
29. Wong, D., andW. Korz. 2008. Translating an Antagonist of Chemokine Receptor CXCR4: from bench to bedside. Clin. Cancer Res. 14: 7975-7980
30. Hassan, S., M. Buchanan, K. Jahan, A. Aguilar-Mahecha, L. Gaboury, W. J. Muller, Y. Alsawafi, A. A. Mourskaia, P. M. Siegel, O. Salvucci, and M. Basik. 2011. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer 129: 225-232
31. Huang, E. H., B. Singh, M. Cristofanilli, J. Gelovani, C. Wei, L. Vincent, K. R. Cook, and A. Lucci. 2009. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J. Surg. Res. 155: 231-236
32. Gupta, S. K., and K. Pillarisetti. 1999. Cutting edge: CXCR4-Lo: molecular cloning and functional expression of a novel human CXCR4 splice variant. J. Immunol. 163: 2368-2372
33. Burger, J. A., and T. J. Kipps. 2006. CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767
34. Broxmeyer, H. E., C. M. Orschell, D. W. Clapp, G. Hangoc, S. Cooper, P. A. Plett, W. C. Liles, X. Li, B. Graham-Evans, T. B. Campbell, et al. 2005. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 201: 1307-1318
35. Gil, M., M. Seshadri, M. P. Komorowski, S. I. Abrams, and D. Kozbor. 2013. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc. Natl. Acad. Sci. USA 110: E1291-E1300
36. Kirn, D. H., and S. H. Thorne. 2009. Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer. Nat. Rev. Cancer 9: 64-71
37. Parato, K. A., C. J. Breitbach, F. Le Boeuf, J. Wang, C. Storbeck, C. Ilkow, J. S. Diallo, T. Falls, J. Burns, V. Garcia, et al. 2012. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol. Ther. 20: 749-758
38. Vanderplasschen, A., E. Mathew, M. Hollinshead, R. B. Sim, and G. L. Smith. 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95: 7544-7549
39. Yang, Y., C. T. Huang, X. Huang, and D. M. Pardoll. 2004. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5: 508-515
40. Zhu, J., J. Martinez, X. Huang, and Y. Yang. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109: 619-625
41. Wang, H., N. G. Chen, B. R. Minev, and A. A. Szalay. 2012. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stemlike cells in comparison to breast cancer cells. J. Transl. Med. 10: 167
42. Janát-Amsbury, M. M., J. W. Yockman, M. L. Anderson, D. G. Kieback, and S. W. Kim. 2006. Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res. 26(4B): 2785-2789
43. Goncharenko-Khaider, N., D. Lane, I. Matte, C. Rancourt, and A. Piché. 2010. The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 29: 5523-5536
44. Schneider-Gädicke, A., and E. Schwarz. 1986. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 5: 2285-2292
45. Jensen, F. C., A. J. Girardi, R. V. Gilden, and H. Koprowski. 1964. Infection of Human and Simian Tissue Cultures with Rous Sarcoma Virus. Proc. Natl. Acad. Sci. USA 52: 53-59
46. Chakrabarti, S., J. R. Sisler, and B. Moss. 1997. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097
47. Gil, M., M. Bieniasz, M. Seshadri, D. Fisher, M. J. Ciesielski, Y. Chen, R. K. Pandey, and D. Kozbor. 2011. Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice. Br. J. Cancer 105: 1512-1521
48. Gil, M., M. Bieniasz, A. Wierzbicki, B. J. Bambach, H. Rokita, and D. Kozbor. 2009. Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J. Immunol. 183: 6808-6818
49. Liang, Z., J. Brooks, M.Willard, K. Liang, Y. Yoon, S. Kang, and H. Shim. 2007. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem. Biophys. Res. Commun. 359: 716-722
50. Ferrara, N. 2004. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9(Suppl. 1): 2-10
51. Ferrara, N. 2004. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25: 581-611
52. Shen, G. H., M. Ghazizadeh, O. Kawanami, H. Shimizu, E. Jin, T. Araki, and Y. Sugisaki. 2000. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 83: 196-203
53. Liu, B. Y., I. Soloviev, P. Chang, J. Lee, X. Huang, C. Zhong, N. Ferrara, P. Polakis, and C. Sakanaka. 2010. Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS ONE 5: e8611
54. Orimo, A., and R. A. Weinberg. 2006. Stromal fibroblasts in cancer: A novel tumor-promoting cell type. Cell Cycle 5: 1597-1601
55. Nozawa, H., C. Chiu, and D. Hanahan. 2006. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl. Acad. Sci. USA 103: 12493-12498
56. Curiel, T. J., P. Cheng, P. Mottram, X. Alvarez, L. Moons, M. Evdemon-Hogan, S. Wei, L. Zou, I. Kryczek, G. Hoyle, et al. 2004. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 64: 5535-5538
57. Nathan, C. 2006. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol. 6: 173-182
58. Youn, J. I., M. Collazo, I. N. Shalova, S. K. Biswas, and D. I. Gabrilovich. 2012. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91: 167-181
59. Breitbach, C. J., J. M. Paterson, C. G. Lemay, T. J. Falls, A. McGuire, K. A. Parato, D. F. Stojdl, M. Daneshmand, K. Speth, D. Kirn, et al. 2007. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 15: 1686-1693
60. Wei, S., I. Kryczek, L. Zou, B. Daniel, P. Cheng, P. Mottram, T. Curiel, A. Lange, and W. Zou. 2005. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65: 5020-5026
61. Singh, P., Y. Yao, A. Weliver, H. E. Broxmeyer, S. C. Hong, and C. H. Chang. 2008. Vaccinia virus infection modulates the hematopoietic cell compartments in the bone marrow. Stem Cells 26: 1009-1016
62. Acharyya, S., T. Oskarsson, S. Vanharanta, S. Malladi, J. Kim, P. G. Morris, K. Manova-Todorova, M. Leversha, N. Hogg, V. E. Seshan, et al. 2012. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150: 165-178
63. Shepherd, T. G., B. L. Thériault, E. J. Campbell, and M. W. Nachtigal. 2006. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat. Protoc. 1: 2643-2649
64. Naito, T., Y. Kaneko, and D. Kozbor. 2007. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. J. Gen. Virol. 88: 61-70
65. Kusumbe, A. P., and S. A. Bapat. 2009. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 69: 9245-9253
66. Kleffel, S., and T. Schatton. 2013. Tumor dormancy and cancer stem cells: two sides of the same coin? Adv. Exp. Med. Biol. 734: 145-179
67. Aguirre-Ghiso, J. A. 2007. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7: 834-846
68. Russell, S. J., K. W. Peng, and J. C. Bell. 2012. Oncolytic virotherapy. Nat. Biotechnol. 30: 658-670
69. Inoue, K., H. Sugiyama, H. Ogawa, M. Nakagawa, T. Yamagami, H. Miwa, K. Kita, A. Hiraoka, T. Masaoka, K. Nasu, et al. 1994. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071-3079
70. Hylander, B., E. Repasky, P. Shrikant, M. Intengan, A. Beck, D. Driscoll, P. Singhal, S. Lele, and K. Odunsi. 2006. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol. Oncol. 101: 12-17
71. Hohenstein, P., and N. D. Hastie. 2006. The many facets of the Wilms' tumour gene, WT1. Hum. Mol. Genet. 15: R196-R201
72. Martínez-Estrada, O. M., L. A. Lettice, A. Essafi, J. A. Guadix, J. Slight, V. Velecela, E. Hall, J. Reichmann, P. S. Devenney, P. Hohenstein, et al. 2010. Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. Nat. Genet. 42: 89-93
73. Mani, S. A., W. Guo, M. J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, et al. 2008. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715
74. Ning, N., Q. Pan, F. Zheng, S. Teitz-Tennenbaum, M. Egenti, J. Yet, M. Li, C. Ginestier, M. S. Wicha, J. S. Moyer, et al. 2012. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 72: 1853-1864
75. Dhodapkar, M. V., R. M. Steinman, M. Sapp, H. Desai, C. Fossella, J. Krasovsky, S. M. Donahoe, P. R. Dunbar, V. Cerundolo, D. F. Nixon, and N. Bhardwaj. 1999. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104: 173-180.